While no statistically significant differences were observed in full‐field visual evoked potential (VEP) latency between treatment and placebo groups in either intention‐to‐treat or per‐protocol populations, exploratory analysis using multifocal VEP indicated a nominally significant improvement with opicinumab.
1
—
—